Neurodegenerative Disease Market Report 2026

Neurodegenerative Disease Market Overview

• Neurodegenerative Disease market size has reached to $57.23 billion in 2025 • Expected to grow to $88.5 billion in 2030 at a compound annual growth rate (CAGR) of 9% • Growth Driver: Increase In Clinical Trial Activity Fueling The Growth Of The Market Due To Rising Research Investments • Market Trend: Emergence Of Real-time Personalized Treatments Enhancing Patient Outcomes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Neurodegenerative Disease Market?

Neurodegenerative disease refers to a group of disorders characterized by the progressive degeneration of the structure and function of the nervous system, including the brain and spinal cord. Its primary goal is to understand, diagnose, and treat these conditions through advancements in biotechnology, pharmaceuticals, and medical technology. This field aims to slow disease progression, improve patient outcomes, and reduce the healthcare burden. It supports aging populations, enhances neurological care, and contributes to a sustainable, technology-driven healthcare system. The main types of neurodegenerative diseases are parkinson's disease, alzheimer's disease, multiple sclerosis, Huntington's disease, and amyotrophic lateral sclerosis. Parkinson's disease is a progressive neurological disorder that affects movement control due to the loss of dopamine-producing brain cells. These conditions are treated using various types of drugs such as N-methyl-D-aspartate (NMDA) receptor antagonists, cholinesterase inhibitors, dopamine agonists, and immunomodulatory drugs. The routes of administration include oral, injectable, transdermal, and other methods. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels. The key end-users are hospitals, retail providers, and online platforms.

What Is The Neurodegenerative Disease Market Growth Forecast?

The neurodegenerative disease market size is expected to see strong growth in the next few years. It will grow to $88.5 billion in 2030 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to advancements in gene and cell therapy, rising r&d in novel neuroprotective drugs, expansion of clinical trial networks, integration of ai for early diagnosis and patient monitoring, increasing adoption of personalized medicine approaches. Major trends in the forecast period include rising prevalence of neurodegenerative disorders, increasing investment in drug development and clinical trials, adoption of targeted and personalized therapies, growth in awareness and early diagnosis programs, expansion of home-based and outpatient care solutions.

Global Neurodegenerative Disease Market Segmentation

1) By Disease Type: Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Amyotrophic Lateral Sclerosis 2) By Drug Type: N-methyl-D-aspartate Receptor antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Acetylcholinesterase (AChE) Inhibitors, Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor, Selective Serotonin Reuptake Inhibitor (SSRIs), Other Drug Types 3) By Route of Administration: Oral, Injectable, Transdermal, Other Routes Of Administration 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels 5) By End-User: Hospital, Retail, Online Subsegments: 1) By Parkinson's Disease: Idiopathic Parkinson's Disease, Familial Parkinson's Disease, Early-Onset Parkinson's Disease, Parkinsonism 2) By Alzheimer's Disease: Early-Onset Alzheimer's Disease, Late-Onset Alzheimer's Disease, Familial Alzheimer's Disease (FAD), Inflammatory Subtype, Non-Inflammatory Subtype, Cortical Subtype 3) By Multiple Sclerosis (MS): Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), Progressive-Relapsing MS (PRMS) 4) By Huntington's Disease: Adult-Onset Huntington's Disease, Juvenile Huntington's Disease 5) By Amyotrophic Lateral Sclerosis (ALS): Classical ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS, Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), Juvenile ALS, ALS-Parkinsonism-Dementia Complex (ALS-PDC)

What Is The Driver Of The Neurodegenerative Disease Market?

The increase in research and clinical trials is expected to propel the growth of the neurodegenerative disease market going forward. Clinical trials refer to research studies conducted with human participants to evaluate the safety, efficacy, and potential side effects of new treatments, drugs, or medical devices. The increase in research and clinical trials is primarily driven by the rising demand for new treatments to address evolving healthcare needs and improve patient outcomes. Clinical trials support neurodegenerative disease research by providing critical data on the safety and effectiveness of new treatments, helping to advance therapeutic development and improve patient outcomes. For instance, in December 2024, according to a report published by the Association of the British Pharmaceutical Industry (ABPI), a UK-based association, the number of UK industry clinical trials initiated rose by 3.7% in 2023 compared to 2022. Therefore, the increase in research and clinical trials is expected to propel the growth of the neurodegenerative disease industry.

Key Players In The Global Neurodegenerative Disease Market

Major companies operating in the neurodegenerative disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Biogen Inc., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics Inc., Voyager Therapeutics Inc., AC Immune SA, Amylyx Pharmaceuticals Inc., Sage Therapeutics Inc., Alzheon Inc.

Global Neurodegenerative Disease Market Trends and Insights

Major companies operating in the neurodegenerative disease market are focusing on developing innovative products such as next-generation adaptive Deep Brain Stimulation (aDBS) systems, aiming to improve treatment precision, enhance disease-modifying effects, and increase patient quality of life. Next generation adaptive deep brain stimulation (aDBS) systems are advanced neurostimulation devices designed to provide real-time, personalized treatment for Parkinson's disease by dynamically adjusting stimulation parameters based on neural feedback, optimizing therapeutic effects, and minimizing side effects for improved patient outcomes. For instance, in February 2025, Medtronic, a US-based medical technology company, received approval from the U.S. Food and Drug Administration (USFDA) for the world's first adaptive deep brain stimulation (aDBS) system for Parkinson's disease. This approval pertains to the premarket approval (PMA) application for the Percept RC neurostimulator with BrainSense technology, which automatically adjusts therapy in response to a patient's brain signals. The system is clinically validated to provide symptom relief for advanced Parkinson's disease patients and represents a significant advancement in personalized neuromodulation therapies.

What Are Latest Mergers And Acquisitions In The Neurodegenerative Disease Market?

In December 2024, AbbVie, a US-based biopharmaceutical company, acquired Aliada Therapeutics for an undisclosed amount. With this acquisition, AbbVie aims to advance potentially disease-modifying therapies for Alzheimer’s disease and strengthen its neuroscience pipeline by leveraging Aliada’s novel blood-brain barrier-crossing drug delivery platform. Aliada Therapeutics is a US-based company that develops precision medicines for neurological conditions.

Regional Insights

North America was the largest region in the neurodegenerative disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neurodegenerative Disease Market?

The neurodegenerative disease market consists of revenues earned by entities through services such as biotechnology research, pharmaceutical development, diagnostic solutions, medical technologies, and patient care advancements aimed at understanding, diagnosing, and treating neurodegenerative conditions. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurodegenerative disease market also includes sales of pharmaceuticals, biotechnology treatments, medical devices, and diagnostic tools aimed at managing and treating neurodegenerative conditions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neurodegenerative Disease Market Report 2026?

The neurodegenerative disease market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neurodegenerative disease industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.